-
Equillium secures up to $50 million to advance inflammatory drug EQ504
-
Equillium adds cryptocurrency to treasury strategy amid cash concerns
-
Equillium (EQ) Announces Feedback from the FDA
-
Leerink Partners Downgrades Equillium (EQ) to Market Perform
-
Equillium (EQ) Announces Results of the Phase 3 EQUATOR Study of Itolizumab
-
Jones Trading Downgrades Equillium (EQ) to Hold
-
Equillium (EQ) Maintains Rights to Itolizumab Following Ono Partnership
-
Equillium, Inc. (EQ) Tops Q2 EPS by 16c
-
Equillium (EQ) Reports Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab
-
Deutsche Bank New Quarterly Feature Called 'Fresh Money List' Picks, 17 Additions

